Sell-rated reports

287 tickers rated Sell
NewestHighest Score Ranks all reports in this rating group by score, highest first.
Diageo plc
DEO·Consumer Staples
C ★★Sell
Current$99.76
Nov 8, 2026

Diageo's powerful global beverage brands and restructuring savings offer turnaround potential, but sustained U.S. spirits weakness, elevated leverage, and reduced near-term cash flow limit investment appeal.

Score
64
OUTFRONT Media Inc.
OUT·Real Estate
C ★★Sell
Current$30.79
Nov 8, 2026

OUTFRONT Media benefits from scarce advertising locations, rising digital monetization, and improving cash flow, but a premium historical valuation, significant leverage, and cyclical advertising demand constrain its investment appeal.

Score
64
Viatris Inc.
VTRS·Healthcare
C ★★Sell
Current$19.91
Nov 8, 2026

Viatris generates substantial free cash flow and is transitioning toward higher-value medicines, but manufacturing disruptions, acquisition execution risk and substantial historical valuation expansion limit its current investment appeal.

Score
64
QUALCOMM Incorporated
QCOM·Technology
C ★★Sell
Current$165.41
Nov 7, 2026

Qualcomm's wireless patents, automotive growth, and emerging AI data-center business offer long-term upside, but falling handset sales, squeezed margins, and weaker free cash flow undermine the near-term investment case.

Score
64
LandBridge Company LLC
LB·Energy
C ★★Sell
Current$65.10
Nov 7, 2026

LandBridge owns scarce Permian Basin acreage that generates high-margin recurring royalties and offers digital infrastructure upside, but demanding valuation and acquisition-related leverage constrain its investment appeal.

Score
64
Medline Inc.
MDLN·Healthcare
C ★★Sell
Current$39.64
Nov 7, 2026

Medline's integrated medical-surgical distribution network and strong organic growth provide durable expansion potential, but margin pressure, leverage, and a demanding valuation constrain its near-term investment appeal.

Score
64
Royalty Pharma plc
RPRX·Healthcare
C ★★Sell
Current$67.30
Nov 7, 2026

Royalty Pharma offers a scalable pharmaceutical royalty franchise with strong cash generation and reinvestment opportunities, but its historically elevated valuation, finite royalty lives, and leverage weaken the current risk-reward balance.

Score
64
Takeda Pharmaceutical Company Limited
TAK·Healthcare
C ★★Sell
Current$20.91
Nov 2, 2026

Takeda's established specialty medicines, recovering profitability, and shareholder dividends support long-term cash generation, but patent erosion, soft underlying growth, and an elevated historical cash-flow multiple limit investment appeal.

Score
64
Belden Inc.
BDC·Technology
C ★★Sell
Current$105.70
Nov 1, 2026

Belden offers exposure to industrial automation, enterprise networking, and data center infrastructure growth, but acquisition-driven leverage and uncertain RUCKUS integration returns constrain its near-term investment appeal.

Score
64
LKQ Corporation
LKQ·Consumer Discretionary
C ★★Sell
Current$18.56
Nov 1, 2026

LKQ's global aftermarket distribution network and low valuation offer recovery potential, but severe European execution failures, declining earnings, and withdrawn guidance undermine confidence in a sustainable turnaround.

Score
64
CRH plc
CRH·Materials
C ★★Sell
Current$90.81
Nov 1, 2026

CRH owns a durable network of construction-materials assets positioned for long-term infrastructure demand, but weakening margins, elevated acquisition commitments, and uncertain near-term cash-flow growth constrain its investment appeal.

Score
64